hotspot -WSS

hotspot

author：focus 2025-09-05 05:55:21 - browse：7

Photo illustration of Fyodor Urnov surrounded by DNA strands. -- health coverage from STAT — Christine Kao/STAT

Researchers attending gene therapy meetings over the past couple years were liable to bump into a svelte, graying scientist explaining in emphatic, Russian-inflected English that the U.S. was wasting the grand potential of CRISPR gene editing.

Fyodor Urnov, the scientist in question, estimates he gave the talk 30 to 40 times: to fellow researchers, pharma executives, Food and Drug Administration officials, congressional staff, journalists, patient advocates. “Anyone who would listen,” he says.

The problem was one of scale. Sure, for-profit companies were developing cures for a small handful of genetic diseases, such as sickle cell disease. But there were hundreds of devastating conditions that CRISPR might be able to cure but that no entity was seriously working on.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： IVG is promising — but it won’t replace IVF quite yet

WSS

Some top drug companies are starting to take action on climate

The biotech scorecard for Q4: 16 stock

House panel takes first step toward fixing drug shortages

What will Novo Nordisk's VC do with its influx of cash?

CRISPR base editing slashes cholesterol levels in monkeys

CDC picks Alphabet's Verily for wasterwater surveillance contract

Wikipedia

hotspot

Wikipedia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

'A game

Medical leaders decry Supreme Court decision on affirmative action

CRISPR base editing slashes cholesterol levels in monkeys

Anesthesiologist group: stop taking Ozempic before surgery

Why the quest to eradicate polio has stumbled

Medical records are filled with copy

FDA weighs limits of animal data in assessing artificial wombs

23andMe had bad news about my health. I wish a person had delivered it

European officials brace for rough respiratory virus season

focus

Congress extends some pandemic preparedness programs

Medicare innovation center doesn’t save money, experts say

Lawsuit highlights wrinkle for disputes over surprise medical bills

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Health insurers' Q3 question: how much care are people getting?

CDC picks Alphabet's Verily for wasterwater surveillance contract

leisure time

focus

explore

Wikipedia